Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis Inc. has announced a five-year strategic supply agreement with MedReleaf Australia, making MedReleaf the exclusive supplier of Aurora's brands in Australia. The partnership covers EUGMP-certified products, including dried flower, oils, and soft gels, without requiring capital investment from Aurora. With Aurora holding a 10% stake in MedReleaf, this move aims to enhance the availability of high-quality medical cannabis for patients in Australia. Both companies are committed to expanding their reach in the rapidly growing Australian medical cannabis market.
Aurora Cannabis Inc. (NYSE: ACB) announced the closing of its bought deal public offering, raising US$137,940,000 by selling 13,200,000 Units at US$10.45 each. This includes 1,200,000 Units from the over-allotment option. Each Unit consists of one common share and half a warrant, with each full warrant allowing the purchase of one common share at US$12.60 for 36 months. Proceeds will be used for general corporate purposes, including debt reduction, aligning with the company's strategy for a strong balance sheet.
Aurora Cannabis has successfully closed its public offering of units, generating US$137,940,000. A total of 13,200,000 units were sold at US$10.45 each, including 1,200,000 units from an over-allotment option. Each unit consists of one common share and a warrant, exercisable at US$12.60 for three years. The proceeds will be used for general corporate purposes, including potential debt reduction. BMO Capital Markets and ATB Capital Markets were the bookrunners for this offering.
Aurora Cannabis has announced a bought deal offering of 12 million units at US$10.45 each, raising approximately US$125 million, led by BMO Capital Markets and ATB Capital Markets. Each unit consists of one common share and half a warrant, with warrants exercisable for three years at US$12.60. The offering, expected to close by January 26, 2021, will help support general corporate purposes and potentially reduce debt. The prospectus will be filed in Canada and the U.S.
Aurora Cannabis Inc. (NYSE: ACB, TSX: ACB) announced a strategic partnership with Great North Distributors Inc., making them the exclusive sales representative for Aurora's brand portfolio in Canada. This collaboration aims to enhance Aurora's market presence and execution capabilities in the cannabis retail sector. Great North's established relationships with provincial and private retailers across Canada and their data-driven sales approach are expected to benefit Aurora significantly. The agreement takes effect on January 25, 2021.
Aurora Cannabis announces a revised credit facility that extends maturity to December 2022 and transitions to a minimum liquidity covenant, enhancing financial flexibility. With approximately $450 million in cash, the company aims for sustainable revenue growth. Adjusted EBITDA loss for fiscal 2021 Q2 is expected to improve despite COVID-19 challenges. Production adjustments at Aurora Sky aim to align with demand for premium products, while a focus on consumer strategy will support long-term profitability.
Aurora Cannabis Inc. has entered a strategic supply agreement with Cantek Holdings, a leader in Israeli medical cannabis, to supply a minimum of 4,000 kgs of dried bulk flower annually for two years, with an option to extend. The co-branded products are aimed at the Israeli market, which is a major importer of medical cannabis. This move positions Aurora in key international markets alongside Germany. The initial shipment occurred on November 16, 2020, enhancing Aurora's brand presence in Israel.
Tikun Olam and Pincanna have partnered to bring Tikun's acclaimed cannabis products to Michigan by Spring 2021. This collaboration aims to leverage Tikun Olam's extensive research on cannabis, including strains such as Avidekel, Midnight, and Erez, alongside Pincanna's expertise in product formulation. Established in 2005, Tikun Olam is recognized globally for its medical cannabis innovations. The partnership emphasizes a commitment to wellness and aims to enhance the accessibility of quality cannabis products for Michigan consumers.
Aurora Cannabis Inc. announced the closing of its overnight marketed public offering, raising US$172.5 million by selling 23 million Units at US$7.50 per Unit. The offering included 3 million Units from the exercise of the underwriters' over-allotment option. Each Unit comprises one common share and one-half common share purchase warrant, exercisable at US$9.00 for 40 months. Proceeds will be allocated towards growth opportunities, working capital, and general corporate purposes.
Aurora Cannabis has successfully completed an overnight marketed public offering, raising US$172.5 million from the sale of 23 million Units at US$7.50 per Unit. This includes the full exercise of the underwriters’ over-allotment option for 3 million Units. Each Unit comprises one common share and half a warrant, allowing for purchase of shares at US$9.00 within 40 months. The proceeds will be utilized for growth opportunities, working capital, and general corporate purposes. The Offering is conducted under the regulatory framework in Canada and the U.S.